Cetuximab plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: The LABELstudy

Clinical Colorectal Cancer

Volumn 9, Issue 5, 2010, Pages 282-289

  Buzaid, Antonio Carlos ^a   De Cerqueira Mathias, Clarissa ^b   Perazzo, Florencia ^c   Simon, Sergio D ^d   Fein, Luis ^e   Hidalgo, Jorge ^f   Murad, Andre M ^g   Esser, Regina ^h   Senger, Stefanie ^h   Lerzo, Guillermo ⁱ  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b Hospital Português   (Brazil)

^c CEMIC   (Argentina)

^d HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^e Centro Oncologico de Rosario   (Argentina)

^f Centro Oncológico de Integración Regional COIR   (Argentina)

^g HOSPITAL VERA CRUZ   (Brazil)

^h MERCK KGAA   (Germany)

ⁱ Clinica de Oncologia de Excelencia (CODE)   (Argentina)

Author keywords

Acne like rash; EGFR; KRAS; Latin America; Neutropenia

Indexed keywords

CETUXIMAB; IRINOTECAN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HISPANIC; HUMAN; HYPOKALEMIA; INJECTION SITE REACTION; INTESTINAL DYSMOTILITY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELENA; METASTASIS; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SKIN MANIFESTATION; SUBILEUS; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING;

EID: 78651080910     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.3816/CCC.2010.n.041     Document Type: Article

References (21)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65.
3. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-9.
4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-71.
5. Van Cutsem E, Kohne C-H, Hitre E, et al. Cetuximab and chemotherapy as inital treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17.
6. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26:5335-43.
7. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
8. Bosetti C, Malvezzi M, Chatenoud L, et al. Trends in cancer mortality in the Americas, 1970-2000. Ann Oncol 2005; 16:489-511.
9. Filozof C, Gonzalez C, Sereday M, et al. Obesity prevalence and trends in Latin-American countries. Obes Rev 2001; 2:99-106.
10. Kain J, Vio F, Albala C. Obesity trends and determinant factors in Latin America. Cad Saude Publica 2003; 19(suppl 1):S77-86.
11. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-13.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
13. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38:29-41.
14. Greenwood M. The natural duration of cancer. Reports on public health and medical subjects. Her Majesty's Stationary Office, London 1926; 33:1-26.
15. Levine MN, Julian JA. Registries that show efficacy: Good, but not good enough. J Clin Oncol 2008; 26:5316-9.
16. Fuchs CS, Moore MR, Harker G, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003; 21:807-14.
17. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8.
18. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12.
19. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14:1128-35.
20. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-60.
21. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-10.